Abstract
Imatinib (Im), a rationally designed inhibitor of the Bcr/Abl kinase as well as other kinases, represents the standard treatment for Bcr/Abl+ malignancies. Im as a single agent, however, is not curative. Flavopiridol (Fl), an investigational cyclin dependent kinase inhibitor, is broadly active in vitro against human leukemia cells (
Blood
91
:2482
,1998
Cancer Res.
61
:5106
,2001
Clin Cancer Res
8
;2976
,2002
Author notes
Corresponding author
2005, The American Society of Hematology
2005
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal